BSX vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BSX presents a classic divergence between deteriorating technicals and strong fundamental growth. While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company exhibits robust revenue (15.9%) and earnings (18.5%) growth. The stock is currently trading near its growth-based intrinsic value ($55.75) and significantly below analyst targets ($96.66), with a highly attractive PEG ratio of 0.66 suggesting undervaluation relative to growth. Despite a severe 6-month price decline, the consistent track record of earnings beats and a low Forward P/E (15.26) support a bullish long-term outlook.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BSX vs LLY: Head-to-Head Comparison
This page compares Boston Scientific Corporation (BSX) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.